Impact of early β-blocker use on the incidence of sepsis and clinical outcomes following cardiac surgery: a retrospective cohort study

TL;DR

This study finds that using beta-blockers early after heart surgery may reduce the risk of sepsis and improve survival rates.

Contribution

The novel contribution is evidence that early β-blocker use after cardiac surgery is associated with reduced sepsis and mortality.

Findings

Early β-blocker use was linked to lower sepsis risk and in-hospital mortality.

Both low and high doses of metoprolol showed reduced postoperative sepsis risk.

Cumulative sepsis incidence was lower in β-blocker users according to competing risk analyses.

Abstract

Sepsis after cardiac surgery represents a severe perioperative complication with high incidence and mortality rates. While the cardioprotective benefits of β-blocker following cardiac surgery are widely recognized, their impact on sepsis development remains unclear. This study aims to investigate the association between early postoperative β-blocker use and the incidence of sepsis, as well as clinical outcomes, in patients undergoing cardiac surgery.

The analysis incorporated data from the MIMIC-IV database, with confounding factors addressed through propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and overlap weighting (OW). Logistic regression models assessed the risk of sepsis and in-hospital mortality, while Cox proportional hazards models evaluated 28-day and 1-year mortality. Kaplan-Meier survival curves and log-rank tests compared survival between groups. Sensitivity analyses using Fine-Gray competing risk models and cumulative incidence functions were performed. Subgroup analyses explored heterogeneity of treatment effects, and metoprolol was further stratified by dose to assess dose-response relationships.

A total of 3,154 patients treated with β-blocker and 5,220 controls were included. Early β-blocker use was associated with a reduced risk of sepsis and lower in-hospital mortality across all methods. For 28-day and 1-year mortality, β-blocker use showed a trend toward risk reduction. Competing risk analyses demonstrated lower cumulative incidence of sepsis in the β-blocker group. Subgroup and dose-response analyses indicated that both low and high doses of metoprolol were associated with reduced postoperative sepsis risk and mortality outcomes.

Early use of β-blocker after cardiac surgery was associated with a lower incidence of sepsis, with potential benefits observed in both short-term and long-term prognosis. These findings provide valuable evidence for optimizing perioperative drug management strategies.

Figures